This cohort consisted of 35 patients (57.4%) with IDH-mutant astrocytoma and 26 (42.6%) oligodendrogliomas IDH mutant 1p19q codeleted. This evidence concerns the gene IDH2 and astrocytoma (excluding glioblastoma).